Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 31 of 176 for:    immunotherapeutic agent | colon cancer

Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03950154
Recruitment Status : Recruiting
First Posted : May 15, 2019
Last Update Posted : June 14, 2019
Sponsor:
Information provided by (Responsible Party):
Tianjin Medical University Cancer Institute and Hospital

Brief Summary:
This study evaluates the effect and safty of PD-1 monoclonal antibody-activated autologous peripheral blood lymphocyte (PD1-T) combined with XELOX and bevacizumab in the first-line treatment of recurrent and metastatic colorectal cancer. Half of participants receive PD1-T combined with XELOX and bevacizumab, while the other half will receive XELOX and bevacizumab.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Drug: Bevacizumab Injection [Avastin] Drug: Oxaliplatin Drug: Capecitabine Biological: PD1-T cells Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 284 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III Clinical Study of PD-1 Monoclonal Antibody-activated Autologous Peripheral Blood T-lymphocyte (PD1-T) Combined With XELOX and Bevacizumab in the First-line Treatment of Recurrent and Metastatic Colorectal Cancer
Actual Study Start Date : June 1, 2019
Estimated Primary Completion Date : June 1, 2021
Estimated Study Completion Date : April 30, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab

Arm Intervention/treatment
Experimental: Arm 1:CIK

Bevacizumab & Oxaliplatin & Capecitabine & PD1-T cells

Bevacizumab,7.5mg/kg,intravenousinfusion,d1; Oxaliplatin,130mg/m2,intravenous infusion,d1; Capecitabine,1g/m2,oral administration,d1-14; PD1-T cells, 1x10^10 (10 billion),intravenous infusion,17; Q3W,after 6 cycles; Bevacizumab, 7.5mg/kg,intravenous infusion,d1; Capecitabine,1g/m2;Oral administration,d1-14; PD1-T cells,1x10^10(10 billion),intravenous infusion,d17; Q3W, maintenance treatment.

Drug: Bevacizumab Injection [Avastin]
Bevacizumab injection
Other Name: Avastin

Drug: Oxaliplatin
Oxaliplatin injection

Drug: Capecitabine
Capecitabine oral agent

Biological: PD1-T cells
PD1-T cells injection
Other Name: PD-1 monoclonal antibody-activated peripheral blood T-lymphocyte

Active Comparator: Arm 2: Control

Bevacizumab & Oxaliplatin & Capecitabine

Bevacizumab,7.5mg/kg,intravenous infusion,d1; Oxaliplatin,130mg/m2,intravenous infusion,d1; Capecitabine,1g/m2,oral administration,d1-14; Q3W,after 6 cycles; Bevacizumab,7.5mg/kg,intravenous infusion,d1; Capecitabine,1g/m2, Oral administration,d1-14; Q3W, maintenance treatment.

Drug: Bevacizumab Injection [Avastin]
Bevacizumab injection
Other Name: Avastin

Drug: Oxaliplatin
Oxaliplatin injection

Drug: Capecitabine
Capecitabine oral agent




Primary Outcome Measures :
  1. Progression-free survival [ Time Frame: 3 years ]
    PFS will be calculated from initiation of treat- ment until first progression, and patients alive in stable state will be censored at the time of last contact.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects who must meet all the following criteria should be selected:

  1. Agreeing to participate in this study and signing a written informed consent.
  2. Male or female,from 18 to 75 years (including 18 and 75 years).
  3. The life expectancy is longer than 3 months and can be followed up.
  4. Patients with metastatic colorectal cancer whose condition has progressed after operation or could not receive radical surgery at initial treatment, will be confirmed by histological /cytological and imaging examinations. According to RECIST 1.1 standard, there will be at least one measurable lesion.
  5. Bevacizumab, oxaliplatin and capecitabine were not used at least 6 months before the first administration of the drug in the patients with metastatic colorectal cancer whose condition has progressed after operation.
  6. ECOG score will be 0 or 1 within 7 days before randomization.
  7. Within 14 days before the start of treatment, the results of laboratory test of blood routine, liver, kidney function and hormone levels must be met the following criteria:

    White blood cells: more than 3.0 × 109/L; Platelets: more than 100 × 109/L; Neutrophils: more than 1.5 × 109/L; Hemoglobin: more than 80g/L; Serum glutamate pyruvate transaminase: less than 2.5 folds of the upper normal limit (ULN); Serum glutamic-oxal (o) acetic transaminase: less than 2.5 × ULN; Serum bilirubin: less than 1.25 × ULN; Serum creatinine: less than 1.25 × ULN. Cortisol and thyroid function will be in the normal range.

  8. The toxicity and side effects of previous chemotherapy will must be alleviated to grade 1 or below (except hair loss).If the subjects received major surgical treatment or radiotherapy of > 30 Gy, they must recover from the toxicity or complications of these interventions, that is, they can be enrolled after 6 months.
  9. Female subjects must take effective contraceptive measures throughout the study period; serum or urine pregnancy test results must be negative during screening and the whole study period.
  10. Male subjects should take effective contraceptive measures from the beginning of treatment to within 6 months after the end of treatment.

Exclusion Criteria:

Subjects who meet any of the following criteria could not participate in this study:

  1. Bevacizumab or oxaliplatin or capecitabine were used within 6 months before the first use of the study drug.
  2. Patients received major surgery or local radiotherapy of more than 30 Gy within six months before the first use of the drug; received local radiofrequency, ablation, cryotherapy or radiotherapy of 30 Gy or less within one month before the first use of the drug; or received anti-tumor monoclonal antibody (mAb), chemotherapy and targeted small molecule therapy within one month before the first use of the drug. Patients with metastases who can undergo radical surgery.
  3. Other malignant tumors needed treatment within five years.
  4. Allogeneic tissue/organ transplantation.
  5. Participating in research drug therapy within 4 weeks before the first administration of the trial.
  6. Systemic glucocorticoid therapy or any other form of immunosuppressive therapy (except glucocorticoid preconditioned with docetaxel) is being administered within 3 days before the first administration of the experimental therapy.
  7. Previous treatment with PD-1/PD-L1 antibodies.
  8. Over the past two years, patients with active autoimmune diseases requiring systemic treatment, such as the use of corticosteroids, or immunosuppressants. Substitution therapy (such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary dysfunction) is not a systemic treatment.
  9. Having bleeding tendency, high risk of bleeding or coagulation dysfunction, having a history of thrombosis within 6 months and/or hemoptysis within 3 months; being treated with full oral and/or parenteral anticoagulants and thrombolysis agents (preventive use of anticoagulants is permitted); having used aspirin or other non-steroidal anti-inflammatory drugs that inhibit platelet function within 10 days; / MR imaging showed that the tumors surrounded or invaded the large vessel lumen.
  10. Patients with congenital or acquired immunodeficiency (e.g. HIV-infected persons), active hepatitis B (HBV-DNA > 10^3 copies/ml) or hepatitis C (hepatitis C antibody positive), and HCV-RNA higher than the detection limit of the analytical method.
  11. Poorly controlled hypertension (systolic pressure 150 mmHg and/or diastolic pressure 100 mmHg), previous hypertension crisis and hypertensive encephalopathy, and severe cerebrovascular diseases.
  12. Non-healing wounds, active peptic ulcer, tracheoesophageal fistula, gastrointestinal perforation and abdominal abscess within 6 months.
  13. Subjects with active central nervous system (CNS) metastases and/or cancerous meningitis.
  14. Patients with active infections requiring systemic intravenous therapy.
  15. Mental illness or other illnesses, such as uncontrollable heart disease or pulmonary disease, diabetes, etc.
  16. Subjects who are known to be allergic to any of the constituents of the drug being studied.
  17. Subjects with a recent history of drug abuse (including alcohol) within one year.
  18. Compliance is poor and can not cooperate with clinical research.
  19. Female subjects who are pregnant or breastfeeding, or who are expected to be pregnant during the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03950154


Contacts
Layout table for location contacts
Contact: Xiubao Ren, MD. PhD. 86-22-23340123 ext 3173 liangcoh@163.com
Contact: Liang Liu, MD. 86-22-23340123 ext 3172 renxiubao@tjmuch.com

Locations
Layout table for location information
China, Tianjin
Tianjin Medical University Cancer Institute and Hospital Recruiting
Tianjin, Tianjin, China, 300060
Contact: Liang Liu, MD.    86-22-23340123 ext 3172    liangcoh@163.com   
Contact: Xiubao Ren, MD. PhD.    86-22-23340123 ext 3173    renxiubao@tjmuch.com   
Sponsors and Collaborators
Tianjin Medical University Cancer Institute and Hospital
Investigators
Layout table for investigator information
Study Chair: Xiubao Ren, MD. PhD. Tianjin Medical University Cancer Institute and Hospital

Layout table for additonal information
Responsible Party: Tianjin Medical University Cancer Institute and Hospital
ClinicalTrials.gov Identifier: NCT03950154     History of Changes
Other Study ID Numbers: B2019-023-01
First Posted: May 15, 2019    Key Record Dates
Last Update Posted: June 14, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Tianjin Medical University Cancer Institute and Hospital:
effcet
safety
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Colonic Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Modulating Agents
Physiological Effects of Drugs
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Bevacizumab
Capecitabine
Oxaliplatin
Antibodies
Antibodies, Monoclonal
Angiogenesis Inhibitors
Growth Substances
Growth Inhibitors
Immunologic Factors
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action